Impaired wound healing is a frequent problem in diabetes. Hyperglycemia may be an operative mechanism, but a link between glycemic control and wound healing has never been established. Wounds in db/db mice have been extensively studied. This study was undertaken to see if plasma glucose was a predictor of wound healing. An excisional wound was made (149 db/db mice). Wound closure was studied versus metabolic variables. The animals were weeks (mean ± standard error of the mean), obese ( ？g), and hyperglycemic (fasting plasma glucose ？mmol/L). Wound closure at day 13 was . In linear mixed model analyses neither fasting plasma glucose nor its change from start to end of experiment was a significant predictor of wound closure ( , , 95% CI: ？0.01 to 0.31 and , , 95% CI: ？0.11 to 0.23, resp.). However, increase in body weight significantly and independently predicted wound closure (for weight change, , , 95% CI: 0.06 to 0.38). This study strongly suggests that wound healing in db/db mice is independent of prevailing glycemia but dependent on anabolic changes such as weight gain over time. 1. Introduction Impaired wound healing—a well-known problem in diabetes—has been extensively studied in animals [1, 2]. One model, which has been explored for this purpose, is the genetically leptin receptor deficient, diabetic db/db mouse with characteristics such as obesity, transient hyperinsulinemia, insulin resistance, severe hyperglycemia, and impaired wound healing [2–8]. Hyperglycemia is one factor that may be implicated in impaired wound repair. Clinical guidelines advocate optimization of metabolic control to facilitate wound healing [9]. A retrospective study in humans suggested that glycated hemoglobin (A1C) predicted healing rates in diabetic wounds [10]. However, as far as we know, direct evidence of a link between glycemic control and healing is lacking [11]. In the db/db mouse model, a few studies have addressed the possible impact of hyperglycemia on wound healing [6, 12, 13]. They included up to 31？db/db mice from one or two age groups, and baseline body weight but not weight change was assessed. No significant associations between metabolic parameters and wound healing were observed [6]. In the present study we included 149？db/db mice, aged 6–16 weeks, with the aim of testing whether fasting plasma glucose at baseline, the change in fasting plasma glucose, or other metabolic parameters, including weight change, were associated with wound closure. 2. Materials and Methods 2.1. Animals Diabetic C57BL/KsBom-db/db mice were studied. All animals were purchased
References
[1]
W. H. Goodson and T. K. Hunt, “Studies of wound-healing in experimental diabetes-mellitus,” Journal of Surgical Research, vol. 22, no. 3, pp. 221–227, 1977.
[2]
D. G. Greenhalgh, K. H. Sprugel, M. J. Murray, and R. Ross, “PDGF and FGF stimulate wound healing in the genetically diabetic mouse,” American Journal of Pathology, vol. 136, no. 6, pp. 1235–1246, 1990.
[3]
D. L. Coleman, “Diabetes-obesity syndromes in mice,” Diabetes, vol. 31, supplement 1, part 2, pp. 1–6, 1982.
[4]
G.-H. Lee, R. Proenca, J. M. Montez et al., “Abnormal splicing of the leptin receptor in diabetic mice,” Nature, vol. 379, no. 6566, pp. 632–635, 1996.
[5]
M. Berdal, H. I. Appelbom, J. H. Eikrem et al., “Aminated β-1,3-D-glucan improves wound healing in diabetic db/db mice,” Wound Repair and Regeneration, vol. 15, no. 6, pp. 825–832, 2007.
[6]
R. K. Trousdale, S. Jacobs, D. A. Simhaee, J. K. Wu, and J. W. Lustbader, “Wound closure and metabolic parameter variability in a db/db mouse model for diabetic ulcers,” Journal of Surgical Research, vol. 151, no. 1, pp. 100–107, 2009.
[7]
M. Berdal, H. I. Appelbom, J. H. Eikrem et al., “Aminated β-1,3-D-glucan has a dose-dependent effect on wound healing in diabetic db/db mice,” Wound Repair and Regeneration, vol. 19, no. 5, pp. 579–587, 2011.
[8]
G. Pietramaggiori, S. S. Scherer, M. Alperovich, B. Chen, D. P. Orgill, and A. J. Wagers, “Improved cutaneous healing in diabetic mice exposed to healthy peripheral circulation,” Journal of Investigative Dermatology, vol. 129, no. 9, pp. 2265–2274, 2009.
[9]
K. Bakker, J. Apelqvist, and N. C. Schaper, “Practical guidelines on the management and prevention of the diabetic foot 2011,” Diabetes/Metabolism Research and Reviews, vol. 28, supplement 1, pp. 225–231, 2012.
[10]
A. L. Christman, E. Selvin, D. J. Margolis, G. S. Lazarus, and L. A. Garza, “Hemoglobin A1c predicts healing rate in diabetic wounds,” Journal of Investigative Dermatology, vol. 131, no. 10, pp. 2121–2127, 2011.
[11]
A. J. M. Boulton, R. S. Kirsner, and L. Vileikyte, “Clinical practice. Neuropathic diabetic foot ulcers,” The New England Journal of Medicine, vol. 351, no. 1, pp. 48–55, 2004.
[12]
P. Schaeffer, A. Bernat, M. Arnone et al., “Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice,” European Journal of Pharmacology, vol. 529, no. 1–3, pp. 172–178, 2006.
[13]
H. Brem, M. Tomic-Canic, H. Entero et al., “The synergism of age and db/db genotype impairs wound healing,” Experimental Gerontology, vol. 42, no. 6, pp. 523–531, 2007.
[14]
J. M. Bland and D. G. Altman, “Statistical methods for assessing agreement between two methods of clinical measurement,” The Lancet, vol. 1, no. 8476, pp. 307–310, 1986.
[15]
D. L. Coleman and K. P. Hummel, “Studies with the mutation, diabetes, in the mouse,” Diabetologia, vol. 3, no. 2, pp. 238–248, 1967.
[16]
D. S. Seres, “Surrogate nutrition markers, malnutrition, and adequacy of nutrition support,” Nutrition in Clinical Practice, vol. 20, no. 3, pp. 308–313, 2005.
[17]
K. P. Hummel, M. M. Dickie, and D. L. Coleman, “Diabetes, a new mutation in the mouse,” Science, vol. 153, no. 3740, pp. 1127–1128, 1966.
[18]
S. Albertson, R. P. Hummel III, M. Breeden et al., “PDGF and FGF reverse the healing impairment in protein-malnourished diabetic mice,” Surgery, vol. 114, no. 2, pp. 368–372, 1993.
[19]
P. G. Reeves, F. H. Nielsen, and G. C. Fahey Jr., “AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet,” Journal of Nutrition, vol. 123, no. 11, pp. 1939–1951, 1993.
[20]
L. Liu, G. P. Marti, X. Wei et al., “Age-dependent impairment of HIF-1α expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells,” Journal of Cellular Physiology, vol. 217, no. 2, pp. 319–327, 2008.
[21]
W. J. Roesler, C. Helgason, M. Gulka, and R. L. Khandelwal, “Aberrations in the diurnal rhythms of plasma glucose, plasma insulin, liver glycogen, and hepatic glycogen synthase and phosphorylase activities in genetically diabetic (db/db) mice,” Hormone and Metabolic Research, vol. 17, no. 11, pp. 572–575, 1985.
[22]
D. B. Sacks, D. E. Bruns, D. E. Goldstein, N. K. Maclaren, J. M. McDonald, and M. Parrott, “Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus,” Clinical Chemistry, vol. 48, no. 3, pp. 436–472, 2002.
[23]
American Diabetes Association, “Standards of medical care in diabetes—2013,” Diabetes Care, vol. 36, supplement 1, pp. S11–S66, 2013.
